Back to top
more

Erytech Pharma SA Sponsored ADR (ERYP)

(Delayed Data from NSDQ)

$7.50 USD

7.50
17,153

-0.02 (-0.27%)

Updated May 3, 2019 03:54 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Erytech Pharma SA Sponsored ADR (ERYP) Upgraded to Buy: Here's Why

by Zacks Equity Research

Erytech Pharma SA Sponsored ADR (ERYP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Erytech (ERYP) Stops Developing Drug in Leukemia, Down 19.6%

by Zacks Equity Research

After evaluating the FDA's feedback, Erytech Pharma (ERYP) halts developing its lead candidate in leukemia. It is also looking for strategic partnerships to leverage its proprietary platform.

Company News for Dec 1, 2021

by Zacks Equity Research

Companies in the news are: CHS, CTRN, IMGN, ERYP

ERYTECH Pharma (ERYP) Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

ERYTECH Pharma S.A. (ERYP) has been struggling lately, but the selling pressure may be coming to an end soon

ERYTECH Pharma (ERYP) Catches Eye: Stock Jumps 7.4%

by Zacks Equity Research

ERYTECH Pharma (ERYP) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Athersys (ATHX) Surges: Stock Moves 8.8% Higher

by Zacks Equity Research

Athersys (ATHX) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Erytech Pharma SA Sponsored ADR (ERYP) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Erytech Pharma SA Sponsored ADR (ERYP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Will ERYTECH Pharma Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor ERYTECH Pharma.

Erytech Pharma Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

Erytech Pharma SA (ERYP) has been struggling lately, but the selling pressure may be coming to an end soon.

Moving Average Crossover Alert: Erytech Pharma

by Zacks Equity Research

Erytech Pharma is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Erytech Pharma Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

Erytech Pharma has been struggling lately, but the selling pressure may be coming to an end soon.

Sanghamitra Saha headshot

6 European Stocks to Shun on Tapered IMF Outlook

by Sanghamitra Saha

IMF lowered its growth projection for in Germany, France and Italy. Time to avoid these sell-ranked stocks?